Monitor shareholder vote outcome and ability to close $10M financing. The stock may face dilution from both the preferred conversion and the new equity raise. Success hinges on clinical validation and commercialization of PanOmics.
Price Chart
Executive Summary
Profusa entered into a $30M asset purchase agreement to acquire the PanOmics multi-omics platform from Bio Insights LLC, paying with non-voting convertible preferred stock. The deal requires shareholder approval and is paired with a planned $10M equity raise. Long-term potential from the platform is offset by dilution risk and execution uncertainty.
Key Financial Metrics
Key Facts
- Aggregate purchase price of $30 million in Series A Convertible Preferred Stock
- Preferred stock is non-voting, convertible after 1 year, subject to shareholder approval
- 5-year lock-up with 1/4 released annually starting on 1st anniversary
- Seller receives 3% royalty on net revenue from PanOmics commercialization
- Shareholder meeting required by June 30, 2026, to approve issuance
- Company will seek $10 million additional equity financing within 30 days of closing
Financial Impact
$30M in stock consideration plus $10M planned equity raise. No cash involved.
Risk Factors
- Shareholder approval may not be obtained, scuttling the deal
- Additional $10M financing could be dilutive or fail to materialize
- No patents transferred; reliance on know-how may limit competitive moat
- Platform not yet commercialized; revenue uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-048039 |
| Document: ea0287686-8k_profusa.htm | 0001213900-26-048039 |
| Document: 0001213900-26-048039-index-headers.html | 0001213900-26-048039 |
| Document: 0001213900-26-048039-index.html | 0001213900-26-048039 |
| Document: 0001213900-26-048039.txt | 0001213900-26-048039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 8-K | — | awaiting T+20 | — | — |
May 26, 2026 21w ago | 8-K | — | awaiting T+20 | — | — |
May 15, 2026 23w ago | 8-K | — | awaiting T+20 | — | — |
May 8, 2026 24w ago | 8-K | — | awaiting T+20 | — | — |
May 1, 2026 25w ago | S-1/A | — | awaiting T+20 | — | — |
Apr 29, 2026 25w ago | 8-K | — | awaiting T+20 | — | — |
Apr 28, 2026 25w ago | S-1 | — | awaiting T+20 | — | — |
Apr 27, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
Apr 24, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
Apr 6, 2026 29w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers